FDA Escalates Recall of Compounded Tirzepatide Injections from Apothecary Pharma
Apothecary Pharma LLC has voluntarily recalled 22 vials of compounded tirzepatide injections nationwide due to sterility concerns. The FDA upgraded the recall to Class II on October 10, 2026, following a December 2025 warning letter citing serious deficiencies that put patients at risk. While the risk of serious harm is considered small, users are advised to stop using affected lots and contact prescribers for disposal instructions.